drugset / Trial / NCT01611155

Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy

NCT01611155

Completed 50 enrolled Mayo Clinic
RandomizedParallel-groupDouble-blindSupportive care

Summary

You are being asked to take part in this research study because you are going to be treated with oxaliplatin chemotherapy as part of your standard care. Oxaliplatin commonly causes neuropathy (numbing, tingling and/or pain).The purpose of this study is to compare the effects, good and/or bad, of venlafaxine with a placebo (an inactive agent) on oxaliplatin-induced neuropathy (numbing, tingling and/or pain)

Timeline

Start
2012-02-17
Primary completion
2014-03-07
Completion
2015-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Venlafaxine Small molecule 37.5 mg Oral

Indications